Front page
Nothing from your lists
What covered companies filed with the SEC, day by day.
Nothing from your lists
+ 31 more
Nothing from your lists
Cambium Networks Corp · “Upon filing of the Notice of Appointment, the appointment of David Shambrook, Gordon Thomson, Joe Barry and James Woodhead of RSM UK Restructuring Advisory LLP as administrators (the “Administrators”) of CNL became effective.”¶1
Elicio Therapeutics, Inc. · “The Board of Directors of Elicio Therapeutics, Inc. (the “Company”) has established November 12, 2026 as the date of the Company’s 2026 annual meeting of stockholders (the “Annual Meeting”).”¶1
Power REIT · “The Board of Trustees of Power REIT (the “Trust”) has established October 27, 2026 as the date of the Trust’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).”¶1
Nothing from your lists
Nothing from your lists
Nothing from your lists
Nothing from your lists
On June 30, 2026, the Company completed its merger with House of Doge Inc., which became a wholly-owned subsidiary, and 75,902,985 shares of Common Stock were issued and outstanding following closing.¶2¶3¶4¶5
On July 1, 2026, the Company issued 9,000,000 shares of Common Stock, of which 7,875,000 shares are in dispute as the Company seeks their return for cancellation.¶6
On September 9, 2026, Nasdaq notified the Company that its stock failed the $1.00 minimum bid requirement, giving it until March 8, 2027, to regain compliance.¶7¶8¶9¶10
On August 31, 2026, Timothy Stebbing’s employment as Chief Technology Officer was terminated, and he continued to serve as a member of the Board of Directors.
The appointment of David Shambrook, Gordon Thomson, Joe Barry and James Woodhead of RSM UK Restructuring Advisory LLP as administrators of CNL became effective upon filing the Notice of Appointment.¶1
The Administrators will attempt to sell the Company’s assets, including some or all business lines, while remaining CNL group entities are anticipated to be wound up in locally administered processes.¶1¶2
On September 11, 2026, the Company reduced its global workforce by 260 employees, or 53.6% of its total global workforce, effective immediately, with no severance payments offered or made.¶3
Vibhu Vivek’s employment as Senior Vice President, Products, was terminated because his role was eliminated.¶4
Elicio Therapeutics established November 12, 2026 as the date of its 2026 annual meeting of stockholders.¶1
Stockholder proposals, director nominations, and other matters for the annual meeting must be received by the Company’s Secretary by September 24, 2026.¶2¶3
Stockholders soliciting proxies for director nominees other than the Company’s nominees must provide the required Rule 14a-19 notice by September 24, 2026.¶4
Power REIT set October 27, 2026 for its 2026 Annual Meeting and September 11, 2026 as the record date for shareholders entitled to notice and voting.¶1
Because the meeting date changed by more than 30 days from the August 27, 2025 annual meeting, shareholder proposals under Rule 14a-8 must be received by September 15, 2026.¶2¶3
Nominations for trustee or other business outside the Rule 14a-8 process must be delivered by September 24, 2026, following the expected September 16, 2026 mailing of meeting notice.¶4
On September 9, 2026, Sionna’s Board approved a restructuring focused on SION-451 and SION-2222, reducing the workforce by approximately 46% and winding down the SION-719 add-on program.¶2
The Company estimates approximately $6.4 million in restructuring and related charges, with workforce and vendor wind-down activities substantially completed by the end of the third quarter of 2026 and cash payments continuing into the fourth quarter.¶3
Sionna announced plans to advance SION-451 and SION-2222 into a Phase 2a proof-of-concept trial expected to initiate in the first quarter of 2027.¶1¶4
The Company ended Q2 2026 with approximately $268.3 million in cash, cash equivalents, and marketable securities, and estimates its cash runway will extend into the second half of 2029.¶5
The Company and Yorkville mutually terminated the SEPA effective September 11, 2026.¶1
Under the SEPA, the Company could issue and sell Yorkville up to $15.0 million of common shares, with no outstanding borrowings, advance notices, or shares to be issued at termination.¶1
No fees were due by either party in connection with the termination, and Yorkville Securities, LLC remains a sales agent under the Equity Distribution Agreement.¶1
On April 30, 2026, Rainmaker and Larchwood and 2752128 mutually terminated consulting agreements effective at 11:59 p.m., with accrued obligations remaining payable.¶1¶2¶3
The schedules listed obligations of C$26,181.93 and US$248,921.61 for Larchwood and C$7,033.18 and US$259,905.92 for 2752128 as of April 30, 2026.¶4
Effective May 1, 2026, Michael O’Connor became Interim Chief Executive Officer while continuing as Interim Chief Financial Officer, and Kelly White became Interim Vice President, Finance.¶5¶6
Ross, Larchwood and 2752128 surrendered vested options without consideration, while unvested portions were forfeited; the options covered 1,924,192, 3,330,332 and 3,330,332 shares, respectively.¶7¶8¶9
Effective September 10, 2026, Rainmaker Worldwide Inc. and Larchwood Management Partners Inc. mutually terminated the Interim Chief Executive Officer Services Agreement, and no further monthly service fees accrue after termination.¶1¶2¶3
Final accrued amounts through September 10, 2026 were US$10,833.33 of service fees and C$139.41 of approved unreimbursed business expenses, with interest at 10% per annum beginning September 11, 2026 until paid.¶4¶5
Michael O’Connor resigned as director, Chairman of the Board, Interim Chief Executive Officer and principal executive officer, citing health concerns; no successor Chairman was appointed.¶6¶7¶8
Ryan D. Moore and Michael A. Skinner joined the Board, which consists of two directors and one vacancy, and the Board appointed Skinner President and Treasurer and Moore Secretary effective September 10, 2026.¶9¶10¶11¶12
On September 14, 2026, the Company completed the initial closing of its private placement, receiving gross proceeds of approximately $11.3 million and issuing 16,502,870 shares, pre-funded warrants for 23,498,156 shares, and common warrants for 20,000,514 shares.¶1¶2
On September 14, 2026, the Company redeemed the Yorkville Note by paying Yorkville an aggregate redemption amount of approximately $4.6 million, terminating the note.¶3
The Board appointed Dr. Patrick Soon-Shiong and Mr. James Banaag as directors and new Board members, effective as of the Initial Closing on September 14, 2026.¶4
Nant purchased 13,005,334 shares, 22,392,896 pre-funded warrants and 17,699,115 common warrants for approximately $10.0 million, and agreed to purchase additional securities for $10.0 million upon a Milestone Event.¶5
On September 9, 2026, Stewards’ Board and holders of all issued and outstanding Series A Preferred Stock approved an amendment to the Series A COD by written consent.¶2¶3
On September 10, 2026, the Company filed the COD Amendment with the Nevada Secretary of State, and it became effective upon filing.¶4¶1
The amendment replaced the 9.99% Maximum Percentage with 100% and deleted the sentence allowing changes by written notice effective on the 61st day.¶5
On September 10, 2026, NextNRG filed a Certificate of Amendment effecting a one-for-ten (1-for-10) reverse split of its issued and outstanding common stock.¶1
Effective at 12:01 a.m. on September 14, 2026, every 10 shares automatically converted into one share, and the stock began trading under NXXT on a post-split basis.¶1
The Reverse Split will reduce outstanding shares from approximately 168.4 million to approximately 16.8 million, while fractional entitlements are rounded up and options and warrants are proportionately adjusted.¶2¶3
On September 11, 2026, First Citizens filed a certificate of designation establishing its 7.500% Non-Cumulative Perpetual Preferred Stock, Series F.¶2¶3
Series F Preferred Stock dividends accrue at 7.500% per annum through September 15, 2031, and reset thereafter at the five-year treasury rate plus 2.894%.¶4¶5
The Company agreed to sell 300,000 Depositary Shares, each representing a 1/100th ownership interest in Series F Preferred Stock, and closed the offering on September 14, 2026.¶2¶1
Series F Preferred Stock ranks senior to common stock and junior preferred stock and has a liquidation preference of $100,000 per share.¶6¶7
Elmet closed the Department of War transactions on September 14, 2026, receiving $200 million initially and committing to up to $250 million in additional preferred-stock funding.¶1¶2¶3
Elmet issued 200,000 shares of Class A Preferred Stock and warrants for up to 5,675,506 and 1,891,835 Common Stock shares at initial exercise prices of $0.001 and $15.92 per share.¶4¶5¶6
Department of War investors received the exclusive right to elect one of nine directors, while common stockholders will elect only eight; Class A Preferred Stock has 19.9% voting power at the Initial Closing Date.¶7¶8¶9
Elmet entered into a DLA agreement requiring minimum $150 million of tungsten sales over five years, with DLA discretion to purchase up to $1.85 billion more and an additional two-year option.¶10¶11
On September 14, 2026, Ondas entered into a Share Purchase Agreement and acquired 100% of Gate Technologies Ltd. and Bron Technologies sp. z.o.o.¶1¶2
The purchase price was $105.0 million in cash and 10,689,655 shares of common stock, plus $25 million in working capital adjustment, with approximately $22.5 million issued within nine (9) months.¶2
The Shareholders may earn up to $185,000,000 in contingent earn-out payments over two years after the Closing Date, payable in Common Stock.¶3
The Consideration Shares were exempt from registration under Regulation S as sales to non-U.S. investors outside the United States.¶4¶5
Veracyte entered into a merger agreement with Convergent on September 10, 2026, and completed the acquisition on September 14, 2026, adding UroAmp and proprietary urine tumor DNA technology.¶2¶3¶1
Veracyte paid Convergent securityholders aggregate cash consideration of $150 million, subject to purchase price adjustments, and may pay up to $30 million based on specified UroAmp milestones.¶4
Veracyte issued a press release announcing the acquisition, which adds Convergent’s UroAmp platform and proprietary urinary tumor DNA technology to its product portfolio.¶5¶6¶7
Magnolia completed its acquisition of WildFire Energy on September 10, 2026.¶2¶3¶1
The purchase price comprised $2,570 million in cash, 32,203,000 shares of common stock and the assumption of the 2029 Notes.¶4¶5¶6¶3
Magnolia Oil & Gas Operating LLC assumed the obligations under the 2029 Notes, which have $600.0 million aggregate principal amount, bear interest at 7.500% per annum and mature on October 15, 2029.¶7¶8¶9¶10
Magnolia issued the equity consideration under the Securities Act Section 4(a)(2) exemption and agreed to register the resale of those shares, subject to a 30-day lock-up period for WildFire Energy.¶11¶12
Quince Therapeutics completed the sale of Quince Therapeutics SpA, certain AIDE and eDSP intellectual property, and related machines and systems to Ayma Therapeutics for $450,000 in cash on September 8, 2026.¶1
Charles Ryan’s employment ended on September 8, 2026, and the Company agreed to pay him a lump-sum cash amount of $1,014,489.04 within thirty (30) days after the Separation Agreement becomes effective, subject to his release not being revoked.¶2¶3¶4
On September 8, 2026, Z Squared completed its acquisition of Paradox Data, LLC and issued Seller 5,000 shares of Series A Convertible Preferred Stock with an aggregate stated value of $5,000,000.¶1
The Target Company leased the existing building and approximately three-acre parcel in El Dorado, Arkansas, to Seller for $1.00 per year, with a one-time relocation payment of $500,000 and a lease term no later than the second anniversary.¶2¶3
The acquired Union County Campus has an electric service agreement providing up to 8,000 kVA on an interruptible basis, while the Company’s development plan targets up to approximately 150 MW of AI-ready capacity over time.¶4¶5
The Company issued the Series A Preferred Stock without registration, with a conversion price of $7.45 per share of Common Stock and an 8.0% cumulative dividend payable in cash or in kind at the Company’s election.¶6¶7
